PRTC News and Press, PureTech Health plc From 01/14/22

Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as “GLS” on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 PureTech...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Daphne Zohar, Founder and Chi...

PureTech to initiate registration-enabling studies with LYT-100 for the treatment of IPF with a streamlined 505(b)(2) development path that includes a dose-ranging study in IPF patients and a Phase 3 study in IPF patients Veteran IPF and pulmonary drug development expert, Paul...

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Registration Statement filed in connection with pr...

Three clinical-stage, wholly-owned candidates being advanced across range of indications, including two Phase 2 trials of LYT-100 (deupirfenidone), a Phase 1/2 trial of LYT-200 (anti-galectin-9 mAb) and a Phase 1 study of LYT-300 (oral allopregnanolone) Key milestones achieved...

Data demonstrating ability to achieve systemic exposure following oral administration shared at American College of Neuropsychopharmacology (ACNP) Annual Meeting Results support potential of PureTech’s Glyph TM technology platform to enable oral administration for a...

LYT-300 is the first candidate from the Glyph TM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biothe...

Plenity ® is transforming weight management with a clinically proven approach made from naturally derived building blocks As Chief Nutrition Officer, Bauer will focus on educating healthcare professionals and offering nutrition counseling to Plenity members ...

Gelesis’ new commercial manufacturing facility is now producing Plenity® at large scale, enabling supply to meet the growing demand PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage bioth...

LYT-100 well-tolerated at all doses studied with a favorable PK profile; maximum tolerated dose not determined; additional studies underway to evaluate higher doses Phase 2 enrollment of LYT-100 in patients with Long COVID 1 respiratory complications expected to complete b...